SPDR Gold Trust vs Immunovant Inc. Common Stock — how do they compare? SPDR Gold Trust trades at $384.63 (market cap $141.59B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: SPDR Gold Trust is far larger — about 21.4× Immunovant Inc. Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Immunovant Inc. Common Stock for 0 Days on average.
| GLD | IMVT | |
|---|---|---|
Market Cap | $141.59B | $6.62B |
Volume | 7,008,541 | 1,131,364 |
52-Week High | $495.90 | $44.96 |
52-Week Low | $362.32 | $17.03 |
Typical Hold Time | 74 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.72B |
Signals from Pluang's Aura AI — not financial advice
GLD is trading at $375.88, down 1.66% over the past 24 hours amid broader pressure from rising Treasury yields and a stronger U.S. dollar. The technical picture remains bearish with key support at $372 and resistance at $378. Recent news highlights gold's struggle to maintain momentum despite safe-haven demand, with weak payrolls data failing to spark a sustained rally.
The outlook for GLD remains challenged by persistent headwinds from elevated interest rates and dollar strength, though some analysts see tactical buying opportunities at current levels. Key risks include further Fed rate hikes and declining investor sentiment, while potential catalysts include geopolitical tensions and inflation concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →